


## About Us

OBPHARM is an HKU spinoff dedicated to developing innovative peptide- and monoclonal antibody (mAb)-based therapeutics for obesity and related medical complications. During the past over 30 years, we have adopted a biomarker-based approach for drug discovery and development.

## Focus Areas

- **Obesity and related diseases**
- **Artificial Intelligence**
- **Peptide and Antibody Therapeutics**



## Products

- **OB001, a First-in-Class peptide drug for the treatment of obesity** (PCT Patent Application No. PCT/IB2021/053309; United States Patent Application No. 18/555,201; Chinese Patent Application No. 202180096978.0)
- **OB002, a First-in-Class mAb drug for the treatment of heart failure** (US patent No 7,645,616; US patent No 8,030,097; US patent No 8,481,032 B2; US2019/0309054 A1, US 16/345,432; US 63/045,174)

## Project Team



### Founder/CEO: Yu Wang

Professor in Pharmacology and Pharmacy with over 30 years experience in biomarker/drug target discovery



### Founder/CTO: Xuechen Li

Professor in Protein/Peptide Chemistry and world-leading expert in innovative chemical synthesis of biologics



### Chief Advisor: Garth J.S. Cooper

Founder of Amylin Pharmaceuticals and experienced in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases.